Premium
Plerixafor added to G‐CSF allows mobilization of a sufficient number of hematopoietic progenitors without impacting the efficacy of TCR ‐alpha/beta depletion in pediatric haploidentical and genoidentical donors failing to mobilize with G‐CSF alone
Author(s) -
Kurnikova Elena,
Trakhtman Pavel,
Pershin Dmitry,
Ilyushina Mariya,
Khismatullina Rimma,
Maschan Michael,
Novichkova Galina,
Maschan Alexey
Publication year - 2021
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21891
Subject(s) - plerixafor , medicine , apheresis , filgrastim , progenitor cell , cd34 , granulocyte colony stimulating factor , haematopoiesis , immunology , gastroenterology , pharmacology , stem cell , chemotherapy , cxcr4 , platelet , chemokine , receptor , biology , genetics
Abstract Background Collection of a large number of early hematopoietic progenitors is essential for allogeneic apheresis products intended for TCR‐alpha/beta depletion. Materials and Methods We added plerixafor 0.24 mg/kg body weight (bw) on day 4 of high‐dose filgrastim mobilization 10 hours prior to apheresis in 16 (30.5%) pediatric allogeneic donors who failed to recover a sufficient number of CD34+ cells. Results On day 4 of G‐CSF, the median CD34+ cell count in peripheral blood was 6 per μL (range 4‐9 per μL) in 6 poor mobilizers and 16 per μL (range 12‐19 per μL) in insufficient mobilizers. In all donors, the threshold of 50 CD34+ cells/μL was achieved, and the median increase was 14.8‐fold in poor mobilizers and 6.5‐fold in insufficient mobilizers, whereas it was 3.45‐fold increase in those mobilized with G‐CSF alone. Discussion In all donors, a predefined number of >10 × 10 6 CD34+ cells/kg of recipient bw before depletion was reached in the apheresis product. The use of plerixafor did not affect the purity of further TCR‐alpha/beta depletion. Side effects were mild to moderate and consisted of nausea and vomiting. Conclusion Thus, the safety and high efficacy of plerixafor was proven in healthy pediatric allogeneic hematopoietic cell donors.